I. RDS conceptualization-The biological processes of reward that underlie addiction to substances and all addictive, compulsive and impulsive behaviors are the basis of the RDS conceptualization [5, 6] . RDS then is a deficiency, a hypodopaminergic condition that results from some combination of genetic variations, environmental stressors, and adverse molecular effects or blunting due to prolonged substance use or behavioral habituation [7] [8] [9] . The RDS concept was developed based on animal and human research that explored the molecular biology of neurotransmission, and behavioral genetics [8, 10, 11] . Understanding this concept, explained in the following paragraphs, is central to treating the abnormal psychology of personality and spectrum disorders, as well as, substance and non-substance (behavioral) addictions. To feel ordinary pleasure, complex interactions of neurotransmitters regulate the dopaminergic activity of the brain in the reward center -the mesolimbic system, particularly the nucleus accumbens. Individuals, who suffer from a lack of ordinary pleasure in their lives, are predisposed to use any means; substance or behavior, to activate dopamine release, relieve stress and feel healthy pleasure [12, 13] .
Introduction
We are proposing a generalized approach based on the Reward Deficiency Syndrome (RDS) conceptualization called the Systematic Medical Approach to Reward Transformation (SMART ™ ). This system consists of: early pre-disposition diagnosis (even in children) using the Genetic Addiction Risk Score (GARS) [1] ; a validated RDS questionnaire [2] ; urine drug testing during actual treatment that uses comprehensive analysis of reported drugs to determine compliance with prescription medications and non-abstinence illicit drugs [3] ; and adjunctive treatment with a glutaminergic-dopaminergic optimization nutraceutical (KB220) to prevent relapse by induction of dopamine homeostasis [4] .
This work is licensed under Creative Commons Attribution 4.0 Licens III. The epigenetics of stress and prolonged exposure-In addition to genetic polymorphisms, which reduce the availability of dopamine in the synapse, prolonged stress and long -term substance abuse also result in reduced cascade function and decreased dopamine release and may have a cumulative effect on vulnerability to addiction and other RDS Behaviors [19, 20] . Harmful molecular effects or blunting occur due to prolonged substance use [21, 22] . The repeated release of high amounts of dopamine into the synaptic cleft induces prolonged, heightened postsynaptic receptor activity, resulting in receptor down-regulation and, for this reason, further decreases dopamine function. Also, hypodopaminergic function, caused by genetic variations impacted by epigenetics, can induce impairments in the pre-frontal cortex-cingulated gyrus, which in turn leads to poor judgment and potential habit reinstatement or relapse [20, 22] .
Receptor down-regulation reported, in both obese rats and drug-addicted humans, is the reason habituated addicts require ever increasing substance or behavior to maintain the rewarding effect [20, 23] . However after prolonged abstinence dopamine receptor supersensitivity, an enhanced biochemical response develops, and reinstatement at the previous level of habituation in the case of substance abuse may lead to fatalities [24] . Environmentally induced epigenetic effects on the chromatin structure ofthe DNA due to stress or triggered by cues can increase craving. Stress-triggered craving involves the neurotransmitters corticotrophin-releasing factor and norepinephrine. These neurotransmitters necessitate the abundant release of dopamine (100X times resting state) and subsequently, temporary hypodopaminergic functioning, repeated, or prolonged stress can induce a chronic hypodopaminergic state. Cue-triggered craving involves the basolateral nucleus of the amygdala, the hippocampus, and through glutaminergic activation, causes the increased release of dopamine that if chronic ultimately leads to a hypodopaminergic state. Due to this hypodopaminergic trait (genetic) and state (environmental), it is known that drug intake or aberrant behaviors will escalate [25, 26] .
Genetic addiction risk score (GARS)
The Genetic Addiction Risk Score (GARS), is the first test to accurately predict vulnerability to pain, addiction, and other obsessive and compulsive behaviors, identified as RDS [27] . There is a need to classify patients at genetic risk to alcohol and drug-seeking behavior and relapse before or upon entry to pain and residential and or non-residential chemical dependency programs. Based on an extensive literature review, an addiction risk index consisting of 11 polymorphisms in 10 genes, involved in the neurological processing of reward, were identified and tested. The resulting genetic addiction risk score (GARS) included; six single-nucleotide polymorphisms (SNPs) in the DRD1, DRD2, DRD3, DRD4, COMT, and OPRM1 genes; four simple sequence repeats (SSRs) in the DAT1, DRD4, MAOA, and 5HTT transporter genes; and a dinucleotide polymorphism in the GABRA3 gene [9] . Blum's laboratory sought to address genetic risk for alcohol and drug by evaluating whether the combined effect of reward gene polymorphisms that contribute to a hypodopaminergic trait, associate with RDS related substance abuse risk. Among those who consented to provide a saliva sample for DNA genotyping, 273 (derived from seven centers) also had ASI phenotypic information.
The patient population n=393, 17.6%, 80.7%, and 1.5% scored in the low, moderate and high severity range, respectively. The mean number of GARS alleles was 7.97 (S.D. = 2.34) and ranged between 3 and 17 alleles. The relationship between GARS genotype panel and the Alcohol Risk Severity Score using the Fishers Exact Test revealed a significant predicative relationship (X2 = 8.84, df = 1, p = 0.004, 2-tailed) that remained significant after controlling for age (p < 0.01). A similar, though less robust, relationship was obtained from chi-square (p = 0.05) and linear regression (b = −0.122, t = −1.91, p = 0.10, 2-tailed) analyses of the ASI Drug Severity Risk Score. Blum et al. [28, 29] details the construction of a genetic addiction risk score (GARS ™ ) and its predictive relationship with ASI -MV derived alcohol and drug severity risk scores. Innovative strategies to combat epidemic opioid/opiate abuse, and death, based on the role of dopaminergic tone in pain pathways, are proposed. Sensitivity to pain may reside in the mesolimbic projection system, where genetic polymorphisms associate with a predisposition to pain vulnerability or tolerance. Pharmacogenomic testing of candidate genes like CB1, mu receptors, and PENK might result in pharmacogenomic, personalized solutions, and improved clinical outcomes. Identifying genetic risk for all RDS behaviors, especially in compromised populations, may be a frontline tool to assist municipalities in providing better resource allocation and possibly precision medicine [30] .
RDS questionnaire
In conjunction with Zsolt Demetrovics in the Eötvös Loránd University, Institute of Psychology, Budapest, Hungary, an unpublished, 29 item RDS questionnaire reduced from 51 items generated based on the RDS theory, has been validated in over 1726 individuals attending college. The general reward deficiency factor was associated with gender, sensation seeking and impulsivity. Females show ahigher degree of reward deficiency trait. Greater sensation seeking and impulsivity predict higher degrees of reward deficiency and risk seeking behaviors and are positively associated with sensation seeking and impulsivity [2] .
Pro-Dopamine regulator (KB220)
A glutaminergic-dopaminergic optimization nutraceutical called KB220 has been developed that supports the brain reward system and induces "dopamine homeostasis". This agonistic nutraceutical has been shown to safely provide substantial clinical benefit to the victims of RDS and assist in recovery from addiction to opiates/opioids and other substance and nonsubstance addictions and behaviors [7, 17, [31] [32] [33] . DNA-directed compensatory over expression of the DA D2 receptors (a form of gene therapy) has been shown to result in a significant reduction in alcohol and cocaine craving behavior in drug-preferring rodents [34, 35] and acute in vitro bromocriptine a strong agonist-induced D2 receptor proliferation in rats [36] . KB220 variants formulations have been studied extensively in both animals and humans. Pre-clinical and human trials using a variety of methodologies are reported on in a detailed review article [37] and Table 1 lists the studies of KB220 variants in a multiplicity of RDS populations. Interestingly, in abstinent heroin addicts, a pilot study of a single dose of KB220Z compared to placebo found improvement of the prefrontal-cerebellar-occipital neural network and activation of the NAc [38] .
Conclusion
Recently the hypothesis [39] [40] [41] [42] [43] that KB220Z would enhance resting connectivity patterns between reward and cognitive brain regions was tested in placebo-controlled rsfMRI experiments in the rat. Additionally, qEEG studies in humans found that KB220Z modulates theta power in the anterior cingulate cortex [44, 45] . Double-blind controlled studies and others [37, [46] [47] [48] have demonstrated positive effects on both craving attenuation and relapse prevention [48-50] and enhanced compliance to KB220Z treatment was significant in obese carriers of the D2 receptors A1 allele vs. carriers of the usual complement of DA D2 receptors [51, 52] . The rationale for evaluating KB220Z in the present article application is the evidence of clinical benefit KB220Z can give by epigenetically changing the neuromechanisms involved in producing dopamine homeostasis [53] . Based on this research and current literature new strategies to treat RDS are needed. The traditionally used therapeutic agents have failed to address the reduced connectivity patterns now seen in many addictions and have had limited success in relapse prevention and effective recovery from psychoactive substance abuse [4, 54] . This concept would enable genetic testing and precise treatment of genetic and epigenetic deficits with formulations of KB220 [55,56]. Recovery and good health would be the goal of this SMART, holistic program design, based on this extensive research in a diverse but stable population [57]. In a diverse but stable population like African-Americans as well as other minority groups showing high genetic risk for all RDS behaviors.
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RDS
Reward Deficiency Syndrome First small clinical trial of SAAVE (precursor amino acid loading and enkephalinase inhibition -earliest version of NAAT). Designed to elevate levels of enkephalin(s), serotonin, catecholamines, and GABA, thought to be deficient in alcoholics. Compared to controls those who took SAAVE had lower building up to drink score, required no PRN benzodiazepines, ceased having tremors 24 hours earlier, and had less depression. Of 247 Outpatients in a very-low-calorie fasting program 130 who were having difficulty attaining their desired weight or maintaining their desired weight constituted the experimental group who took PhenCal ™ and the rest 117 took vitamins 117 were the control group. The PhenCal ™ group compared to the control lost twice as much weight, regained 14.7% of the weight while the control group regained 41.7%, decrease in food cravings for females 70% and males 63%, and decreased in binge eating for females 66% and males 41%. Preliminary evaluation of six randomly selected former eating disordered female clients (three were also chemically dependent), contacted at 9 months and 3 years of treatment with amino-acid precursor and enkephalinase inhibition therapy. All 6 reported initial benefit, one relapsed at 6 months the other 5 all sustained, and in some cases exceeded expectations. 98% of 100 patients similarly treated and evaluated reported significant improvement in both mood and reduced substance craving. A combination of Trexan (a narcotic antagonist) and amino-acids was use to detoxify either methadone or heroin addicts. Results were dramatic in terms of significantly enhancing compliance to continue taking Trexan. Trexan alone for rapid detoxification the average number of days of compliance calculated on 1000 patients is 37 days. 12 subjects tested, receiving both the Trexan and amino-acid therapy taking the combination for an average of 262 days. Suggests coupling amino-acid therapy and enkephalinase inhibition, while blocking the delta-receptors with a pure narcotic antagonist as a novel method to induce rapid detox in chronic methadone patients and prevent relapse, and testing this hypothesis with the sublingual combination of the partial opiate mu receptor agonist buprenorphine. Consumption of large quantities of alcohol or carbohydrates (carbohydrate bingeing) stimulates production and usage of dopamine within the brain. Obesity is due to the need to make up for inadequate dopaminergic activity in the reward center of the brain. This has been called reward deficiency syndrome (RDS) used to categorize such genetic biologic influences on behavior. RDS must be addressed at the same time as behavioral modifications are implemented to adequately treat obese patients. In this small observational trial; 24 individuals completed a survey on which they documented 15 categories of benefit during their experience with a GenoTrim a NAAT formulation customized to DNA. Statistical analysis of the survey results demonstrated that stress reduction lead to improved sleep, enhanced energy, and improved focus and performance, reduced appetite, loss of unwanted weight, decreased body inches, and enhanced well-being.
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Chen TJ, Blum In an open clinical study Amino-Acid Enkephalinase Inhibition Nutraceutical improved symptomatology of 600 recovering Alcoholics. Emotional and behavioral recovery scores significantly improved after administration of oral and intravenous Synaptamine. Mean reductions for craving, depression, anxiety, anger, fatigue, lack of energy and crisis were all significantly greater than 50% (p<0.001).
Chen TJH, Blum K, Kaats G, et al. Chromium Picolinate (Crp) A putative Anti-Obesity Nutrient Induces Changes In Body Composition As Function Of The Taq1 Dopamine D2 Receptor
Gene. Gene Ther Molboil 11; 161-170.
Chromium Picolinate (CrP) was tested against placebo in groups of obese patients tested for the Taq1 Dopamine D2 Receptor Gene. In carriers of the DRD2 A2 genotype weight loss and other changes in body composition were significant. They were not significant for patients with the A1/A1 or A1/A2 allele. These results suggest that the dopaminergic system, specifically the density of the D2 receptors, confers a significant differential therapeutic effect of CrP in terms of weight loss and change in body fat. Synaptamine Complex Variant [KB220] ™ as an activator of the meso-limbic system and administration significantly reduces or "normalizes" aberrant electrophysiological parameters of the reward circuitry site. Based on our QEEG studies presented herein we cautiously suggest that long-term activation of dopaminergic receptors (i.e., DRD2 receptors) will result in proliferation of D2 receptors leading to enhanced "dopamine sensitivity" and an increased sense of happiness. Oral KB220 showed an increase of Alpha activity and an increase low Beta activity similar to 10-20 sessions with Neurofeedback. This study examined the effects of combined administration of tyrosine, lecithin, L-glutamine and L-5-hydroxytryptophan (5-HTP) on heroin withdrawal syndromes and mental symptoms in detoxified heroin addicts. The results showed that the insomnia and withdrawal scores were significantly improved over time in participants in the intervention group as compared with those in the control group. A greater reduction in tension-anxiety, depressiondejection, anger-hostility, fatigue-inertia and total mood disturbance, and a greater increase in their vigor-activity symptoms were found at day 6 in the intervention group than in the control placebo group In 129 patients a combination of IV and oral NAAR therapy (generic KB220) were assessed for Chronic Abstinence Symptom Severity (CASS) Scale over a 30-day period. Three scales were constructed based on this factor analysis: Emotion, Somatic, and Cognitive. All three scales showed significant improvement (P=0.00001) from pre-to post -treatments: t=19.1 for Emption, t=16.1 for Somatic, and t= 14.9 for impaired cognitive. A two-year follow-up in a subset of 23 patients showed: 21(91%) were sober at 6 months with 19(82%) having no relapse; 19 (82% were sober at one year with 18 (78%) having no relapse; 21(91%) were sober at two-years post-treatment with 16(70%) having no relapse. Note: these results of cause do not reflect any other recovery skills utilized by the patients including 12 steps program and Fellowship.
